TREATMENT REGIMENS Sample Clauses

TREATMENT REGIMENS. Induction therapy Each participating center will decide on one of the following three options of first line chemotherapy, of which 4 or 5 cycles will be given: Cisplatin (60 - 100 mg/m(carat)2, day 1) + VP 16 (80 - 120 mg/ m(carat)2, day 1,2 and 3); OR Carboplatin (AUC 4 - 6)* + VP 16 (80 - 120 mg/ m(carat)2, day 1,2 and 3); OR Cyclophosphamide (>= 1000 mg/ m(carat)2, day 1) + Doxorubicin (>= 40 mg/m(carat)2, day 1) + Etoposide (80 - 120 mg/ m(carat)2, day 1, 2 and 3); Chest radiotherapy is mandatory (according to local policy, concomitant or sequential) Prophylactic cranial irradiation is highly recommended for patients with complete response. * Dose (mg) = target AUC (4 - 6) x (Glomerular filtration rate + 25). GFR is based on the Cockxxxx-Xxxxx xxxmula for creatinine clearance: (140-age) X (weight in kg) GFR = ------------------------------ x 0.85 (female) or x 1.00 (male) 72 x serum creatinine mg/100ml 15/102 33 [LOGO] The SILVX xxxdy -------------------------------------------------------------------------------- Trial treatment: Timing: After 5, to a maximum of 7 months from diagnosis and within 6 weeks after completion of ALL induction therapy, responding patients will be RANDOMIZED: STANDARD ARM (OBSERVATION COHORT): Best supportive care, but no cancer specific therapy (cytotoxic, radiation or other tumor reductive therapy) can be given until documented progression of disease EXPERIMENTAL ARM (VACCINATION COHORT):
AutoNDA by SimpleDocs
TREATMENT REGIMENS. 15 4.3 STRATIFICATION AT RANDOMIZATION .................................... 16 5.

Related to TREATMENT REGIMENS

  • Treatment The Asset Representations Reviewer agrees to hold and treat Confidential Information given to it under this Agreement in confidence and under the terms and conditions of this Section 4.08, and will implement and maintain safeguards to further assure the confidentiality of the Confidential Information. The Confidential Information will not, without the prior consent of the Issuer and the Servicer, be disclosed or used by the Asset Representations Reviewer, or its officers, directors, employees, agents, representatives or affiliates, including legal counsel (collectively, the “Information Recipients”) other than for the purposes of performing Reviews of Review Receivables or performing its obligations under this Agreement. The Asset Representations Reviewer agrees that it will not, and will cause its Affiliates to not (i) purchase or sell securities issued by the Seller or its Affiliates or special purpose entities on the basis of Confidential Information or (ii) use the Confidential Information for the preparation of research reports, newsletters or other publications or similar communications.

  • Substance Abuse Treatment Information Substance abuse treatment information shall be maintained in compliance with 42 C.F.R. Part 2 if the Party or subcontractor(s) are Part 2 covered programs, or if substance abuse treatment information is received from a Part 2 covered program by the Party or subcontractor(s).

  • Surface Treatments The Project Area is covered by a layer of mulch permeable to air and water, including, but not limited to rock, bark, ungrouted stepping stones and artificial turf manufactured to be permeable or a high- density planting of living groundcover plants. There are no impermeable barriers that would inhibit the passage of air and/or water to the soil. APN: 161-06-701-001 When Recorded, Return To: Southern Nevada Water Authority Conservation Division P.O. Box 99956 MS 110 Las Vegas, Nevada 89193-9956 EXHIBIT “D” CONSERVATION EASEMENT This Grant of Conservation Easement (“Easement”) is made by the Xxxxx County School District, a political subdivision of the State of Nevada, as the grantor, (“Owner”) and the Southern Nevada Water Authority (“Authority”), a political subdivision of the State of Nevada, as the holder.

  • Musculoskeletal Injury Prevention and Control (a) The Hospital in consultation with the Joint Health and Safety Committee (JHSC) shall develop, establish and put into effect, musculoskeletal prevention and control measures, procedures, practices and training for the health and safety of employees.

  • TREATMENT REQUESTED (b) Buyer shall defend, indemnify and hold harmless Myriant from and against all loss, costs, expenses, damages and liability of any kind arising out of any claims of infringement or alleged infringement of any patent or other intellectual property right with respect to (i) the use of Products in any application by Buyer or its affiliates, contract manufacturers or customers, including but not limited to the use of Products alone or in combination with other substances or components; (ii) any modification to the Products by Buyer or its affiliates, contract manufacturers or customers; or (iii) Products furnished, or methods used, by Myriant in accordance with the specifications or instructions furnished by or expressly or implicitly prescribed by Buyer.

  • Public Improvements To the best knowledge of the Transferor Partnership, there are no written or proposed plans to widen, modify, or realign any street or highway or any existing or proposed eminent domain proceedings which would affect the Property in any way whatsoever. To the best knowledge of the Transferor Partnership, there are no presently planned public improvements which would result in the creation of a special improvement or similar lien upon the Property.

  • GARBAGE DISPOSAL, RECYCLING, AND BIODEGRADABLE MATERIALS A. Concessionaire shall be responsible for maintaining the cleanliness of the Concession Premises. Concessionaire shall ensure placement of all garbage and trash generated by the Concession Operation in designated containers and that said containers are emptied daily, or as more frequently required by Department, at a location within the Area designated by Department. Disposal costs from this latter location shall be borne by Department. Concessionaire shall provide such additional trash containers as may be required to keep the immediate Concession Premises clean at all times. The type of trash containers provided by Concessionaire shall be approved by Department prior to use.

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • Vaccination and Inoculation (a) The Employer agrees to take all reasonable precautions, including in-service seminars, to limit the spread of infectious diseases among employees.

  • Future Treatment of Unallowable Costs Unallowable Costs shall be separately determined and accounted for by Xx. Xxxxxxx, and Xx. Xxxxxxx shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by Xx. Xxxxxxx or any of its subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs.

Time is Money Join Law Insider Premium to draft better contracts faster.